CHU Kremlin Bicêtre

At CHU Kremlin Bicêtre, clinical research in immunology and autoimmune disease focuses on conditions such as systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, juvenile idiopathic arthritis, and vasculitis. These studies are designed to test new treatments, improve disease control, and better understand how immune-targeted therapies can relieve symptoms and prevent long-term damage.

• Testing advanced immune-modulating therapies for lupus and Sjögren’s syndrome
• Evaluating treatment strategies for rheumatoid arthritis and juvenile arthritis
• Studying approaches to reduce inflammation in vasculitis and related disorders

Overall, the site contributes to research aimed at making autoimmune care more precise, effective, and better tolerated for both adults and children.

Neurological research at this site covers a wide range of nervous system diseases, including multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated disease, acute stroke syndromes, and rare white-matter disorders such as cerebral adrenoleukodystrophy and Pelizaeus-Merzbacher disease. The trials mainly aim to assess new therapies, slow disease progression, and improve recovery after inflammatory or demyelinating injury.

• Investigating treatments for multiple sclerosis and MOGAD
• Exploring early intervention in childhood stroke and inflammatory arteriopathy
• Studying therapies for rare genetic neurological disorders that affect myelin and brain function

This portfolio reflects a strong interest in both common and rare neurologic conditions, with a focus on preserving function and limiting irreversible damage.

Research in respiratory disease and critical care includes pulmonary arterial hypertension, interstitial lung disease, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and severe asthma. The studies are intended to evaluate new treatments, improve breathing and exercise capacity, and support patients with severe or progressive lung disease.

• Testing therapies for pulmonary arterial hypertension and related vascular lung conditions
• Assessing treatment options for fibrotic lung disease and interstitial lung disorders
• Studying supportive approaches for ARDS and other critical respiratory illnesses

These trials show a broad commitment to improving outcomes in both chronic lung disease and acute life-threatening respiratory failure.

The site also conducts substantial research in hematology, including hemophilia, sickle cell disease, myelodysplastic syndromes, myelofibrosis, polycythaemia vera, and Glanzmann thrombasthenia. These trials often focus on improving bleeding control, reducing transfusion needs, and evaluating therapies for chronic blood disorders and marrow diseases.

• Evaluating new options for hemophilia and other bleeding disorders
• Studying treatments for sickle cell disease and bone marrow disorders such as myelofibrosis
• Assessing ways to improve anemia management and blood cell production

This is an important area of research at CHU Kremlin Bicêtre, with studies aimed at both symptom relief and longer-term disease control.

Clinical trials in digestive system disease, kidney disease, and metabolic disorders include Crohn’s disease, ulcerative colitis, focal segmental glomerulosclerosis, chronic kidney disease, gout, and hypoparathyroidism. The purpose of these studies is to test better therapies, reduce inflammation, and improve organ function and quality of life.

• Studying treatment strategies for inflammatory bowel disease
• Evaluating therapies for kidney disorders and protein loss in the urine
• Testing approaches for metabolic and endocrine conditions such as gout and hypoparathyroidism

These studies reflect a strong translational focus on chronic diseases that require long-term management and careful monitoring.

Research in cardiovascular disease and maternal health includes heart failure, pulmonary embolism, venous thromboembolism, pregnancy hypertension, and pre-eclampsia. These trials are generally designed to improve prevention, refine treatment decisions, and protect both patients and, in pregnancy studies, the developing baby.

• Evaluating therapies for heart failure and pulmonary hypertension
• Studying safer management for blood clots and thrombotic risk
• Testing ways to prevent complications in pregnancy, including pre-eclampsia and premature birth

The breadth of this work highlights the site’s role in both acute care and prevention-focused research across high-risk clinical settings.

Additional studies at the site span neoplasms, virus diseases, and mental disorders, including non-small cell lung cancer, rectal cancer, HIV, Staphylococcus aureus bacteremia, and major depressive disorder. The main goal is to evaluate new treatment options, strengthen infection control, and improve outcomes in complex conditions that affect both physical and mental health.

• Testing new approaches in cancer care, including solid tumors and blood cancers
• Studying therapies for infectious diseases such as HIV and bloodstream infection
• Exploring innovative care for severe depression and other psychiatric conditions

Across these fields, the research program combines treatment innovation with efforts to improve everyday clinical outcomes for patients facing serious and often long-lasting illnesses.